Resultados de un estudio prospective de quimioprofilaxis con Mitomycina-C y BCG alternadas: Respuesta completa, índice de recidivas y de progresión

Gloria Nohales Taurines, Ramón Cortadellas Ángel, Octavio Arango Toro, Oscar Bielsa Gali, Antoni Gelabert Mas

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

OBJECTIVES: The high incidence of recurrence in superficial urothelial cancer warrants the use of chemoprophylaxis; however, the results achieved to date have been unsatisfactory. The present study investigated the possibility of reducing the incidence of recurrence of superficial urothelial cancer post-TUR and disease progression. METHODS/RESULTS: 99 patients were treated with monthly instillations of mitomycia-C and BCG alternately for one year, which commenced three weeks following TUR. The incidence of recurrence and progression were 15.3% and 5.10%, respectively. Treatment was well-tolerated and there were minimum side effects. CONCLUSIONS: Chemoprophylaxis with alternating mitomycin-C and BCG therapy in patients with superficial urothelial cancer achieves good results. It is well-tolerated and few side effects were observed.
Original languageEnglish
Pages (from-to)689-692
JournalArchivos Espanoles de Urologia
Volume49
Issue number7
Publication statusPublished - 1 Sep 1996

Keywords

  • BCG
  • Bladder cancer
  • Mitomycin-C
  • Prospective study

Fingerprint Dive into the research topics of 'Resultados de un estudio prospective de quimioprofilaxis con Mitomycina-C y BCG alternadas: Respuesta completa, índice de recidivas y de progresión'. Together they form a unique fingerprint.

Cite this